{"count": 34, "results": [{"_id": "36628027", "pmid": 36628027, "pmcid": "PMC9822529", "title": "The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review", "journal": "Cureus", "authors": ["Boddepalli CS", "Gutlapalli SD", "Lavu VK", "Abdelwahab Mohamed Abdelwahab R", "Huang R", "Potla S", "Bhalla S", "AlQabandi Y", "Nandula SA", "Khan S"], "date": "2022-12-07T00:00:00Z", "doi": "10.7759/cureus.32286", "meta_date_publication": "2022 Dec", "meta_volume": "14", "meta_issue": "12", "meta_pages": "e32286", "score": 50270.652, "text_hl": "However, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ was less effective in acute renal replacement therapy, @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@, and/or @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@, with a one-year risk of acute dialysis. ", "citations": {"NLM": "Boddepalli CS, Gutlapalli SD, Lavu VK, Abdelwahab Mohamed Abdelwahab R, Huang R, Potla S, Bhalla S, AlQabandi Y, Nandula SA, Khan S. The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review Cureus. 2022 Dec;14(12):e32286. PMID: 36628027", "BibTeX": "@article{36628027, title={The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review}, author={Boddepalli CS and Gutlapalli SD and Lavu VK and Abdelwahab Mohamed Abdelwahab R and Huang R and Potla S and Bhalla S and AlQabandi Y and Nandula SA and Khan S}, journal={Cureus}, volume={14}, number={12}, pages={e32286}}"}}, {"_id": "36923829", "pmid": 36923829, "pmcid": "PMC10009720", "title": "Extrapyramidal syndromes of chronic kidney disease and dialysis (diabetic uremic syndrome) with reversible parkinsonism and lentiform fork sign: A case report and literature review including metformin-induced encephalopathy", "journal": "Heliyon", "authors": ["Sakurai T", "Nishida H"], "date": "2023-03-03T00:00:00Z", "doi": "10.1016/j.heliyon.2023.e14255", "meta_date_publication": "2023 Mar", "meta_volume": "9", "meta_issue": "3", "meta_pages": "e14255", "score": 50270.625, "text_hl": "We should ascertain whether @SPECIES_9606 @@@patients@@@ with @DISEASE_Basal_Ganglia_Diseases @DISEASE_MESH:D001480 @@@EPS@@@-CKDD are taking @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ because it may be inappropriately prescribed for @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@. ", "citations": {"NLM": "Sakurai T, Nishida H. Extrapyramidal syndromes of chronic kidney disease and dialysis (diabetic uremic syndrome) with reversible parkinsonism and lentiform fork sign: A case report and literature review including metformin-induced encephalopathy Heliyon. 2023 Mar;9(3):e14255. PMID: 36923829", "BibTeX": "@article{36923829, title={Extrapyramidal syndromes of chronic kidney disease and dialysis (diabetic uremic syndrome) with reversible parkinsonism and lentiform fork sign: A case report and literature review including metformin-induced encephalopathy}, author={Sakurai T and Nishida H}, journal={Heliyon}, volume={9}, number={3}, pages={e14255}}"}}, {"_id": "36145361", "pmid": 36145361, "pmcid": "PMC9505840", "title": "Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4", "journal": "Pharmaceuticals (Basel)", "authors": ["Yang A", "Lau ESH", "Wu H", "Ma RCW", "Kong APS", "So WY", "Luk AOY", "Fu AWC", "Chan JCN", "Chow E"], "date": "2022-09-13T00:00:00Z", "doi": "10.3390/ph15091140", "meta_date_publication": "2022 Sep 13", "meta_volume": "15", "meta_issue": "9", "meta_pages": "", "score": 50266.293, "text_hl": "...2.2. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Use and Risk of @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESKD@@@", "citations": {"NLM": "Yang A, Lau ESH, Wu H, Ma RCW, Kong APS, So WY, Luk AOY, Fu AWC, Chan JCN, Chow E. Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4 Pharmaceuticals (Basel). 2022 Sep 13;15(9):. PMID: 36145361", "BibTeX": "@article{36145361, title={Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4}, author={Yang A and Lau ESH and Wu H and Ma RCW and Kong APS and So WY and Luk AOY and Fu AWC and Chan JCN and Chow E}, journal={Pharmaceuticals (Basel)}, volume={15}, number={9}}"}}, {"_id": "34917782", "pmid": 34917782, "pmcid": "PMC8645906", "title": "Focal brain lactate accumulation in metformin-induced encephalopathy without systemic lactic acidosis: A case report suggesting mitochondrial vulnerability in lentiform fork sign", "journal": "eNeurologicalSci", "authors": ["Hanazono A", "Takahashi Y", "Sanpei Y", "Kamada S", "Sugawara M"], "date": "2021-11-29T00:00:00Z", "doi": "10.1016/j.ensci.2021.100383", "meta_date_publication": "2021 Dec", "meta_volume": "25", "meta_issue": "", "meta_pages": "100383", "score": 50259.28, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ causes @DISEASE_Brain_Diseases_Metabolic @DISEASE_MESH:D001928 @@@metabolic encephalopathy@@@ in some @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage chronic kidney disease@@@, resulting in @DISEASE_Consciousness_Disorders @DISEASE_MESH:D003244 @@@impaired consciousness@@@ and @DISEASE_Parkinson_Disease_Secondary @DISEASE_MESH:D010302 @@@parkinsonism@@@. ", "citations": {"NLM": "Hanazono A, Takahashi Y, Sanpei Y, Kamada S, Sugawara M. Focal brain lactate accumulation in metformin-induced encephalopathy without systemic lactic acidosis: A case report suggesting mitochondrial vulnerability in lentiform fork sign eNeurologicalSci. 2021 Dec;25():100383. PMID: 34917782", "BibTeX": "@article{34917782, title={Focal brain lactate accumulation in metformin-induced encephalopathy without systemic lactic acidosis: A case report suggesting mitochondrial vulnerability in lentiform fork sign}, author={Hanazono A and Takahashi Y and Sanpei Y and Kamada S and Sugawara M}, journal={eNeurologicalSci}, volume={25}, pages={100383}}"}}, {"_id": "32545901", "pmid": 32545901, "pmcid": "PMC7352798", "title": "Significance of Metformin Use in Diabetic Kidney Disease", "journal": "Int J Mol Sci", "authors": ["Kawanami D", "Takashi Y", "Tanabe M"], "date": "2020-06-14T00:00:00Z", "doi": "10.3390/ijms21124239", "meta_date_publication": "2020 Jun 14", "meta_volume": "21", "meta_issue": "12", "meta_pages": "", "score": 50258.13, "text_hl": "In clinical studies, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use has been shown to be associated with reduced rates of mortality, @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiovascular disease@@@ and progression to @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@ (@<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@) in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ (@DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@CKD@@@). ", "citations": {"NLM": "Kawanami D, Takashi Y, Tanabe M. Significance of Metformin Use in Diabetic Kidney Disease Int J Mol Sci. 2020 Jun 14;21(12):. PMID: 32545901", "BibTeX": "@article{32545901, title={Significance of Metformin Use in Diabetic Kidney Disease}, author={Kawanami D and Takashi Y and Tanabe M}, journal={Int J Mol Sci}, volume={21}, number={12}}"}}, {"_id": "33714781", "pmid": 33714781, "title": "Mechanism and application of metformin in kidney diseases: An update.", "journal": "Biomed Pharmacother", "authors": ["Song A", "Zhang C", "Meng X"], "date": "2021-06-01T00:00:00Z", "doi": "10.1016/j.biopha.2021.111454", "meta_date_publication": "2021 Jun", "meta_volume": "138", "meta_issue": "", "meta_pages": "111454", "score": 50254.586, "text_hl": "As the common pathway for @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ (@DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@CKD@@@) progressing towards @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end-stage renal disease@@@ (@<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@), @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@renal fibrosis@@@ is ameliorated by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, to a great extent dependent on @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@ activation. ", "citations": {"NLM": "Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: An update. Biomed Pharmacother. 2021 Jun;138():111454. PMID: 33714781", "BibTeX": "@article{33714781, title={Mechanism and application of metformin in kidney diseases: An update.}, author={Song A and Zhang C and Meng X}, journal={Biomed Pharmacother}, volume={138}, pages={111454}}"}}, {"_id": "32132005", "pmid": 32132005, "title": "The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.", "journal": "Diabetes Care", "authors": ["Kwon S", "Kim YC", "Park JY", "Lee J", "An JN", "Kim CT", "Oh S", "Park S", "Kim DK", "Oh YK", "Kim YS", "Lim CS", "Lee JP"], "date": "2020-05-01T00:00:00Z", "doi": "10.2337/dc19-0936", "meta_date_publication": "2020 May", "meta_volume": "43", "meta_issue": "5", "meta_pages": "948-955", "score": 50254.492, "text_hl": "RESULTS: All-cause mortality and incident @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@ESRD@@@ were lower in the @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ group according to the multivariate Cox analysis. ", "citations": {"NLM": "Kwon S, Kim YC, Park JY, Lee J, An JN, Kim CT, Oh S, Park S, Kim DK, Oh YK, Kim YS, Lim CS, Lee JP. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care. 2020 May;43(5):948-955. PMID: 32132005", "BibTeX": "@article{32132005, title={The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.}, author={Kwon S and Kim YC and Park JY and Lee J and An JN and Kim CT and Oh S and Park S and Kim DK and Oh YK and Kim YS and Lim CS and Lee JP}, journal={Diabetes Care}, volume={43}, number={5}, pages={948-955}}"}}, {"_id": "33373028", "pmid": 33373028, "pmcid": "PMC8357762", "title": "Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist", "journal": "J Nephrol", "authors": ["Mariano F", "Biancone L"], "date": "2021-08-01T00:00:00Z", "doi": "10.1007/s40620-020-00941-8", "meta_date_publication": "2021 Aug", "meta_volume": "34", "meta_issue": "4", "meta_pages": "1127-1135", "score": 50254.32, "text_hl": "...Pharmacology of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in normal subjects and in @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@chronic renal failure@@@ (adapted from 13,18-20)", "citations": {"NLM": "Mariano F, Biancone L. Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist J Nephrol. 2021 Aug;34(4):1127-1135. PMID: 33373028", "BibTeX": "@article{33373028, title={Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist}, author={Mariano F and Biancone L}, journal={J Nephrol}, volume={34}, number={4}, pages={1127-1135}}"}}, {"_id": "40027456", "pmid": 40027456, "title": "Lentiform Fork Sign Secondary To Metformin-Induced Encephalopathy.", "journal": "J Brown Hosp Med", "authors": ["Santos MA"], "date": "2025-01-01T00:00:00Z", "doi": "10.56305/001c.127261", "meta_date_publication": "2025", "meta_volume": "4", "meta_issue": "1", "meta_pages": "38-40", "score": 50254.047, "text_hl": "We report a case of @DISEASE_Confusion @DISEASE_MESH:D003221 @@@confusion@@@ and @DISEASE_Gait_Ataxia @DISEASE_MESH:D020234 @@@ataxic gait@@@ in a @SPECIES_9606 @@@patient@@@ with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end stage renal disease@@@ and ongoing @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use. ", "citations": {"NLM": "Santos MA. Lentiform Fork Sign Secondary To Metformin-Induced Encephalopathy. J Brown Hosp Med. 2025;4(1):38-40. PMID: 40027456", "BibTeX": "@article{40027456, title={Lentiform Fork Sign Secondary To Metformin-Induced Encephalopathy.}, author={Santos MA}, journal={J Brown Hosp Med}, volume={4}, number={1}, pages={38-40}}"}}, {"_id": "34970149", "pmid": 34970149, "pmcid": "PMC8712936", "title": "Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study", "journal": "Front Pharmacol", "authors": ["Wood S", "Magliano DJ", "Bell JS", "Shaw JE", "Ilomäki J"], "date": "2021-12-14T00:00:00Z", "doi": "10.3389/fphar.2021.794273", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "794273", "score": 50253.355, "text_hl": "Moreover, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ initiators with @<m>DISEASE_Kidney_Failure_Chronic</m> @DISEASE_MESH:D007676 @@@end stage renal disease@@@ had 2.4 times the risk of switching, compared to those without it.", "citations": {"NLM": "Wood S, Magliano DJ, Bell JS, Shaw JE, Ilomäki J. Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study Front Pharmacol. 2021;12():794273. PMID: 34970149", "BibTeX": "@article{34970149, title={Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study}, author={Wood S and Magliano DJ and Bell JS and Shaw JE and Ilomäki J}, journal={Front Pharmacol}, volume={12}, pages={794273}}"}}]}